Walter Alexander | Authors


Third-Line Eribulin Effective, Safe in Metastatic Breast Cancer

November 01, 2016

Among patients with HER2-negative stage IIIb/IV breast cancer who have progressed after a taxane or anthracycline therapy, a multicenter single-arm study of third-line eribulin demonstrated both safety and efficacy.

Recent Results of Nab-Paclitaxel in Breast Cancer Consistent With Phase III Data

November 01, 2016

In the “real world” NABUCCO trial, results with nab-paclitaxel were consistent with those reported in the pivotal trial among patients with metastatic breast cancer who are ineligible to receive anthracycline therapy.